An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Neurology, Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 1 - 65 |
| Updated: | 10/3/2018 |
| Start Date: | August 2016 |
| End Date: | February 2022 |
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The
open-label extension phase only will be described in this record. All participants will
receive the same dose of GWP42003-P. However, investigators may subsequently decrease or
increase the participant's dose until the optimal dose is found.
open-label extension phase only will be described in this record. All participants will
receive the same dose of GWP42003-P. However, investigators may subsequently decrease or
increase the participant's dose until the optimal dose is found.
Key Inclusion Criteria:
- Completion of the GWEP1521 Blinded Phase
We found this trial at
1
site
Click here to add this to my saved trials
